AstraZeneca Pharma India Ltd. — Earnings Release 2024

Nov 13, 2024

==> picture [503 x 53] intentionally omitted <==

November 13, 2024

The Manager – Listing BSE Limited 1[st] Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai 400001

The Manager – Listing National Stock Exchange of India Ltd. Exchange Plaza, 5[th] Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 400051

Dear Sir(s),

Sub: Press Release

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Please find enclosed the press release for the audited financial results for the quarter ended September 30, 2024.

Thanking you,

For AstraZeneca Pharma India Limited

MANAS Digitally signed by MANASA RAMA A RAMA Date: 2024.11.13 16:19:40 +05'30' Manasa. R Company Secretary

==> picture [452 x 64] intentionally omitted <==

News Release

Steady growth and profitability supports AstraZeneca Pharma India Ltd H1 and Q2 financial results; Total Revenue now increased by 969 Mn compared to corresponding quarter of previous year

Bengaluru, November 13, 2024: AstraZeneca Pharma India Limited (‘the Company’), a science-led biopharmaceutical company, announces its financial results for the second quarter ended September 30, 2024. The Company reported strong financial performance, achieving a 31% increase in revenue from operations compared to the same period last year.

Financial performance Summary

Summary	Q1 2024 Apr’24-Jun’24 (Value in INR)	Q2 2024 Jul’24-Sep’24 (Value in INR)	H1 2024 Apr’24-Sep’24 (Value in INR)
Total Revenue from Operations	3,875.2 Mn	4,080.0 Mn	7,955.2 Mn
Profit before exceptional item and tax	424.0 Mn	510.3 Mn	934.3 Mn
Profit after exceptional item and tax	(117.9 Mn)	384.3 Mn	266.4 Mn

Commenting on the performance, Bhavana Agrawal, Chief Financial Officer AstraZeneca Pharma India Ltd , said, “We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31% bringing our H1 revenue from operations to INR 7,955.2 Mn, driven by our portfolio -Oncology, Biopharmaceuticals and Rare Disease. The growth of the company is a derivative of our ambition to bring innovative medicines faster in the country for unmet patient needs”.

Dr. Sanjeev Panchal, Country President & Managing Director, AstraZeneca Pharma India Ltd, said “We are transforming the future of healthcare by unlocking the power of what science can do, for people, society, and planet. With a Growth Through Innovation strategy, we are constantly working towards expanding access to innovative therapies, progressive access strategies, and making healthcare systems resilient in India”.

Key milestones:

• The Company completed 45 years in the country on July 11, 2024 and concluded its 45[th] Annual General Meeting on August 8, 2024.

• Since 2023, the Company has delivered 12 approvals across its portfolio-Oncology, Biopharmaceutical, Rare Disease. Last quarter alone, the company announced:

• After the receipt of Import and Market Permission in September 2023 from Drugs Controller General of India for Palivizumab solution for injection 100mg/ml (r-DNA origin) (50mg/0.5mL & 100 mg/mL) presentations in single dose vials administered through intramuscular route), the Company launched Palivizumab 50mg/0.5mL in October 2024 in India.

• After the receipt of Import and Market permission in May 2023 from Drugs Controller General of India for Tremelimumab concentration for solution for infusion 20 mg/ml (25 mg/ml and 300 mg/15 ml presentations in single dose vials) administered through intravenous route, the company launched Tremelimumab 25 mg/ml in October 2024 in India.

• Permission for sale and distribution in September 2024 for Durvalumab 120mg/2.4 ml and 500mg/10 ml solution for infusion from the Central Drugs Standard Organisation for

News Release

additional indication: “Durvalumab in combination with chemotherapy as neoadjuvant treatment, followed by Durvalumab as monotherapy after surgery, is indicated for the treatment of patients with resectable (tumours 4 cm and/or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements”.

Key People Announcements:

• Mr. Narayan. K. Seshadri, Independent Director of the Company, retired as Director of the Company upon completion of his term of office, at the close of business hours on September 29, 2024.

• Ms. Shilpa Divekar Nirula, Independent Director has been unanimously elected as Chairperson of the Board, effective September 30, 2024.

• Ms. Monica Widhani was appointed as an Additional Director (Independent) on the Board of the Company, with effect from September 25, 2024.

• Dr. Anil Arjundas Kukreja, Vice-President - Medical Affairs and Regulatory at AstraZeneca Pharma India Limited decided to pursue his career outside the organisation and completed his handover period by the close of business hours on September 30, 2024. The Company is looking for a suitable replacement for the said position.

Recognitions| Q2 ’2024:

• Collaborated with Indian Academy of Paediatrics to Raise Awareness on Respiratory Syncytial Virus (RSV) in India.

• Diversity and Inclusion Award 2024 at the 57th OPPI Annual Day.

• Awarded ‘Silver’ for Best Employer for Women in Small Category at the ASSOCHAM 5th Diversity & Inclusion Excellence Awards & Conclave – 2024.

About AstraZeneca Pharma India Ltd

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology and Rare Diseases. Established in 1979 in India, it is headquartered at Bengaluru, Karnataka and has a workforce of over 800 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization. For more information, please visit our website: https://www.astrazeneca.in/ or follow us on LinkedIn: AstraZeneca India.

--END--